Wim van den Brink is emeritus hoogleraar Verslavingszorg bij het Amsterdam UMC, locatie AMC. 

• Verslaving
• Psychiatrische comorbiditeit

• Vermeulen JM, Schirmbeck F, Blankers M, van Tricht M, Bruggeman R, van den Brink W, de Haan L; Genetic Risk and Outcome of Psychosis (GROUP) investigators. Association Between Smoking Behavior and Cognitive Functioning in Patients With Psychosis, Siblings, and Healthy Control Subjects: Results From a Prospective 6-Year Follow-Up Study. Am J Psychiatry. 2018 [Epub ahead of print]
• Van den Brink, W., Addolorato, G., Aubin, H.J., Benyamina, A., Caputo, F., Dematteis, M., Gual, A., Lesch, O.M., Mann, K., Maremmani, I., Nutt, D., Paille, F., Perney, P., Rehm, J., Reynaud, M., Simon, N., Söderpalm, B., Sommer, W.H., Walter, H., Spanagel, R. Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level. Addict Biol. 2018 Jul;23(4):969-986
• Pierce, M., Sutterland, A., Beraha, E.M., Morley, K., Van den Brink, W. Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: A systematic review and meta-analysis. Eur. Neuropsychopharmacol. 2018 Jul;28(7):795-806
• Van Emmerik-van Oortmerssen, K., Vedel, E., Kramer, F.J., Koeter, M.W., Schoevers, R.A., Van den Brink, W. Diagnosing ADHD during active substance use: Feasible or flawed? Drug Alcohol Depend. 2017 Nov 1;180:371-375
• Van den Brink, W. ICD-11 Gaming Disorder: Needed and just in time or dangerous and much too early? J Behav Addict. 2017 Sep 1;6(3):290-292
• Fischer, B., Russell, C., Sabioni, P., Van den Brink, W., Le Foll, B., Hall, W., Rehm, J., Room, R. Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. Am J Public Health. 2017 Aug;107(8):e1-e12
• Mann, K., Torup, L., Sørensen, P., Gual, A., Swift, R., Walker, B., Van den Brink, W. Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy. Eur Neuropsychopharmacol. 2016 Dec;26(12):1941-1949
• Beraha, E.M., Salemink, E., Goudriaan, A.E., Bakker, A., De Jong, D., Smits, N., Zwart, J.W., Geest, D.V., Bodewits, P., Schiphof, T., Defourny, H., Van Tricht, M., Van den Brink, W., Wiers, R.W. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: A multicentre, randomised, double-blind controlled trial. Eur Neuropsychopharmacol. 2016 Dec;26(12):1950-1959
• Cohn, M.D., Viding, E., McCrory, E., Pape, L., Van den Brink, W., Doreleijers, T.A., Veltman, D.J., Popma, A. Regional grey matter volume and concentration in at-risk adolescents: Untangling associations with callous-unemotional traits and conduct disorder symptoms. Psychiatry Res Neuroimaging. 2016 Aug 30;254:180-7
• Machielsen, M.W.J., Veltman, D.J., Van den Brink, W., De Haan, L. Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study. Schizophr Res. 2018 Apr;194:32-38

• President International Collaboration of ADHD and Substance Abuse (ICASA)